According to FMI – an ESOMAR-certified market research firm, the global oligonucleotide API market is estimated to reach US$ 2.46 Billion in 2022, and witness a CAGR of 10.2% through 2030.Demand for oligonucleotide APIs is expected to rise at a high CAGR of 10.2% between 2022 and 2030, owing to the growing need for new drug classes. As a result, the global oligonucleotide API market is expected to grow from $2.46 billion in 2022 to $5.36 billion by the end of 2030.
According to FMI’s analysis, as of now, 100+ oligonucleotide APIs are in the clinical trials’ phase, and regulatory approval is on the cards. Post-approval, the demand for production capacity will witness an exponentiation, thereby driving the oligonucleotide API market through 2030.
Oligonucleotides are being looked upon as the subsequent large group of therapeutics following biologics and molecules. This could be attributed to the assurance on their part to develop drugs at lower costs.
Apart from immune therapy, microbial and cardiovascular infections, and cancer, oligonucleotide APIs are being tried out to treat neurological disorders like Alzheimer’s as well. However, factors like regulatory complexities and timely delivery of oligonucleotides (amidst Covid-19) are acting as restraints.
Get a Sample Copy of Report @
https://www.futuremarketinsights.com/reports/sample/rep-gb-11933
Key Takeaways from Oligonucleotide API Marker Study
- Antisense Oligonucleotides APIs are anticipated to reach US$ 4 Bn by 2030.
- North America and Europe collectively accounted for more than 47% of revenue share in 2019 while Asia Pacific is expected to grow at the fastest rate in the forecast period.
- Increase in use of antisense oligonucleotide APIs (especially post approval from US FDA in 2016) to boost the market in the forecast period
“Inorganic mode of growth coupled with broad therapeutic applications in gene therapy is expected to bolster the oligonucleotide API market” says the FMI analyst.
According to Future Market Insights, the global oligonucleotide API market is expected to decline by 03 Basis Point Share (BPS) in H1-2022 versus H1-2021. In comparison to the projected value for H1-2022, the market will fall by 10 basis points during the forecast period.
Several macro and industrial factors, such as GMP guidelines, product licencing, pharmaceutical and drug regulations, and sustainability, have an impact on the market.
New Product Launches: Key Indicators to Oligonucleotide APIs Market
FMI has analyzed players such as Akcea Therapeutics, Biogen, Sarepta Therapeutics, Jazz Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., and Dynavax Technologies in this report. According to the analysis, these players are consolidating their positions through new product launches.
For instance –
- In Mar 2020, Dynavax entered into collaboration with Clover Biopharmaceuticals for developing a vaccine candidate to combat Covid-19. Clover is into advanced evaluation of its Covid-19 S-Trimer, protein-based coronavirus vaccine candidate and Dynavax has its technical expertise along with proprietary toll-like receptor 9 (TLR9) agonist adjuvant, CpG 1018 for executing this.
- Alnylam Pharmaceuticals, Inc., in 2018, launched Givlaari and Onpattro at the commercial level.
Ask for Customization @
https://www.futuremarketinsights.com/customization-available/rep-gb-11933
Gene Therapy and Oligonucleotide APIs
Synthetic oligonucleotides are being used in gene therapy for inactivating genes that help in propagating the disease. Antisense oligonucleotide APIs are used for disrupting the faulty gene’s transcription.
Also, siRNA could be used for signaling the cell to disrupt faulty mRNA’s translation. Along these lines, Pharmamar, in Jan 2020, signed an agreement with Jazz Pharmaceuticals for selling the API for “lurbinectedin”, one of the late-phase treatments for SCLC (small cell lung cancer) so that the latter could commercialize it.
Want more insights?
The study provides compelling insights on Oligonucleotide API market on basis of API type in detail cover every aspects of the market such as Antisense Oligonucleotides API, Short Interfering RNA (siRNA) API, Phosphorodiamidate Morpholino Oligonucleotides (PMO) API, MiRNA API, Aptamers API, CpG Oligonucleotides API and Others (ON Conjugates (NP), ShRNA, etc.), Marketing Status (Marketed, Clinical Trials (Clinical Phases)), and end users (Pharmaceutical Companies and Biotechnology Companies)) across seven major regions.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Technology Assessment
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
TOC continued..!
Contact Sales for Further Assistance in Purchasing this Report @ https://www.futuremarketinsights.com/checkout/11933
Key Segments of Oligonucleotide API Industry Survey
Oligonucleotide API Market by API:
- Antisense Oligonucleotides APIs
- Short Interfering RNA (siRNA) APIs
- Phosphorodiamidate Morpholino Oligonucleotides (PMO) APIs
- MiRNA APIs
- Aptamers APIs
- CpG Oligonucleotides APIs
- Others (ON Conjugates (NP), ShRNA, etc.)
Oligonucleotide API Market by Marketing Status:
- Marketed
- Clinical Trials (Clinical Phases)
Oligonucleotide API Market by End User:
- Contract Manufacturing Organizations (CMOs)
- Pharmaceutical Companies
- Biopharmaceutical Companies
- Contract Development & Manufacturing Organizations (CDMOs)